Medpace (NASDAQ:MEDP) Announces Quarterly Earnings Results, Beats Expectations By $0.36 EPS

Key Points

• Medpace reported quarterly earnings of $3.86 per share, exceeding analysts' expectations of $3.49, and holds a net margin of 18.74%. The company has also updated its FY 2025 EPS guidance to a range of 14.600-14.860.
• Shares of Medpace experienced a slight increase of 0.2%, reaching $546.74, amidst significant trading volumes exceeding past averages.
• Insider activity has seen President Jesse J. Geiger sell over 41,000 shares, resulting in a notable reduction of his holdings, while institutional investors now own 77.98% of the stock.

Medpace (NASDAQ:MEDP - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported $3.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.36, Zacks reports. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The company had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. During the same period in the previous year, the firm posted $3.01 EPS. The firm's revenue was up 23.7% on a year-over-year basis. Medpace updated its FY 2025 guidance to 14.600-14.860 EPS.

Medpace Trading Up 0.2%

Medpace stock opened at $546.74 on Thursday. The firm has a 50 day moving average of $497.43 and a 200 day moving average of $386.90. Medpace has a 12-month low of $250.05 and a 12-month high of $554.14. The firm has a market capitalization of $15.36 billion, a price-to-earnings ratio of 40.65, a P/E/G ratio of 3.39 and a beta of 1.40.

Analysts Set New Price Targets

A number of analysts have issued reports on MEDP shares. Deutsche Bank Aktiengesellschaft raised their target price on Medpace from $270.00 to $430.00 and gave the stock a "hold" rating in a research report on Wednesday, July 23rd. Rothschild Redb cut Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, September 3rd. Robert W. Baird increased their target price on shares of Medpace from $313.00 to $490.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 23rd. Mizuho raised their price objective on shares of Medpace from $510.00 to $575.00 and gave the stock an "outperform" rating in a report on Friday, October 17th. Finally, UBS Group cut shares of Medpace from a "neutral" rating to a "sell" rating and boosted their price objective for the company from $300.00 to $305.00 in a research note on Tuesday, July 29th. Two analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Reduce" and a consensus price target of $430.60.

Insider Activity at Medpace

In other news, CEO August J. Troendle sold 48,487 shares of the stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $451.69, for a total transaction of $21,901,093.03. Following the completion of the transaction, the chief executive officer directly owned 962,615 shares in the company, valued at approximately $434,803,569.35. This represents a 4.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Stephen P. Ewald sold 3,000 shares of the business's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $450.00, for a total value of $1,350,000.00. Following the transaction, the general counsel directly owned 10,343 shares in the company, valued at approximately $4,654,350. This represents a 22.48% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 107,465 shares of company stock worth $49,720,216 over the last ninety days. 20.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Medpace

Several hedge funds and other institutional investors have recently modified their holdings of MEDP. Geneos Wealth Management Inc. boosted its holdings in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after acquiring an additional 37 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of Medpace by 41.4% during the second quarter. Tower Research Capital LLC TRC now owns 533 shares of the company's stock worth $167,000 after purchasing an additional 156 shares during the last quarter. Florida Financial Advisors LLC purchased a new stake in shares of Medpace during the second quarter valued at $233,000. M&T Bank Corp boosted its stake in shares of Medpace by 3.4% during the second quarter. M&T Bank Corp now owns 939 shares of the company's stock valued at $295,000 after purchasing an additional 31 shares during the period. Finally, Sivia Capital Partners LLC bought a new position in shares of Medpace in the second quarter worth about $296,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.